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This retrospective cohort study aims to describe characteristics of patients with MRONJ, to identify factors associated with
MRONJ development, and to examine variables associated with favourable outcome. Totally 32 patients were followed and
observed: 21 females and 11 males, in the age range 35-84 in the period from 2009 to 2018. Clinical, radiological examination
(Orthopantomograph and CBCT) and biopsy were performed in order to achieve diagnosis. Demographic and clinical variables
were taken into consideration: sex, age, primary disease, medication type, mode of delivery, anatomic location, drug treatment
duration, timing of tooth extraction, chemotherapy, presence of bonemetastasis, aetiology of MRONJ, disease stage, and treatment
modality.MRONJ developed under osteoporosis andmalignant disease in 11 and 21 patients, respectively.MRONJ developmentwas
triggered by tooth extraction or trauma in 30 out of 32 cases, whereas the two patients developedMRONJ spontaneously. Stages I, II,
and III were confirmed in 5 (16%), 18 (58%), and 9 (28%) patients, respectively. Mandible was affected in 23 (72%) patients. MRONJ
was treated in our department by conservative and surgical modality. In this study we found that 65% of all patients were classified
in the cured/improvement group and 35% in the stable/progression group.The female gender, osteoporosis as primary disease, oral
regime intake, shorter period on BPs, earlier stage of disease, and specific anatomic localisation (frontal and premolar maxilla) were
factors associated with better response to therapy and favourable clinical outcome. Comprehensive treatment protocol and further
randomized studies are necessary for further improvements.
1. Introduction
Bisphosphonates (BPs) are medications, frequently pre-
scribed in therapy of various pathological conditions affect-
ing bones. On the other hand, they might give side effects.
Furthermore, bisphosphonate related osteonecrosis of the
jaws (BRONJ) has become very popular topic among clin-
icians because of its unreachable nature and unpredictable
outcome. It was presented in the literature for the first
time in 2003 as one of the most serious side effects of BPs
therapy [1]. Later on, the other drugs have been related to this
serious disease. Medications that cause this severe, difficult
to treat condition of the jaws are now grouped into two
categories: BPs and non-BPs (considering other antiresorp-
tive or antiangiogenic medications) [2]. There are several
similar names describing this pathological condition apart of
BRONJ: MRONJ (Medication Related Osteonecrosis of the
Jaw), ARAONJ (Anti-Bone Resorptive Agents Osteonecrosis
of the Jaw), etc. [3]. Despite being in the focus of the research,
its exact aetiology, pathogenesis, and adequate treatment
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protocol remain controversial. [2] Regardless of great scien-
tific understanding and plenty of published proposals no
consensus regarding the treatment has been achieved yet.
MRONJ has been the most discussed adverse effect of
bisphosphonate therapy in the last decade.This phenomenon
was for the first time detected and described by Marx [1] as a
painful and nonhealing bone exposure.
According to the criteria defined by American Associa-
tion of Oral and Maxillofacial Surgeons (AAOMS), MRONJ
presents with exposed necrotic bone in maxillofacial region
for more than 8 weeks in patients without history of radi-
ation therapy to the orofacial region and without obvious
metastatic lesion in the jaw, which are currently on or were
taking antiresorptive or antiangiogenic agents [2]. AAOMS
also defined staging system for MRONJ and proposed treat-
ment protocol for each stage [2].
It is noticed that MRONJ appears corporately with infec-
tion and usually is induced by local trauma, such as tooth
extraction or other invasive dental procedures. There are
also clinical evidences that the risk of developing MRONJ
increases proportionally to the dosage and duration of med-
ication intake and it is greater in patients with oncological
disease, particularly in combination with chemotherapy [2].
To our knowledge, the cases of MRONJ in the population
of Serbia and Montenegro have not been reported and
described in detail so far.
The purpose of this study is to present MRONJ patients
from Serbia and Montenegro taking into consideration
demographic and clinical findings as well as treatment out-
come.
In order to accomplish this aim the following tasks are
set: (1) to describe the characteristics of a cohort of patients
with MRONJ, (2) to identify the factors associated with the
development of MRONJ, and (3) to identify the variables
associated with favourable outcomes.
2. Material and Methods
2.1. Study Design and Sample. To emphasize the purpose of
the research, the researchers designed and implemented a
retrospective longitudinal cohort study and included patients
diagnosed with MRONJ. Patients who did not showed for
the follow-up for more than 6 months after treatment were
excluded from the study. Total of 32 patients with oral
side effects after bisphosphonates and Sutent (Sunitinib)
use with MRONJ were diagnosed and treated in 9 years
period (2009 and 2018) in two University Hospitals (Clinic
for Maxillofacial Surgery, School of Dental Medicine in
Belgrade (Serbia) and Podgorica (Montenegro)). Twenty-
one were women. The mean age at presentation was 59
years (SD ±11.8 yrs). The age of these patients (pts) ranged
from 37 up to 84, and male to female ratio was shifted
more towards females (21:11). Patients were referred to our
departments because of nonhealing wound in one of the jaw,
after tooth extraction. None of these patients had a history of
radiation therapy to the orofacial region. Twenty-one of them
had underlying malignant disease. Underlying oncological
history included eleven patients with breast carcinoma, four
Table 1: Demographic and clinical characteristics.
Demographic and clinical characteristics
Characteristic Value
Sample size 32 (100)
Gender
Male 11 (34.3)
Female 21 (65.6)
Age
Indication for medication
Malignant disease 21 (65.6)
Nonmalignant disease 11 (34.4)
Medication risk factors
Pamidronate 2 (6.2)
Zoledronic 24 (75)
Antiangiogenic agents 1 (3.1%)
Others (oral BPs) 6 (18.8)
Mode of delivery
IV 21(65.6)
IV + Oral 5 (15.6)
IV + (IV + Oral) 26 (81.25)
Oral 6 (18.8)
Anatomic Location
Mandibular 23 (71.9)
Maxillary 9 (28.1)
Maxilla and mandible 1 (3.1)
Treatment duration
Zoledronate 33.87 ± 23.05
Pamidronate 6±0
Others (oral BPs) 34.9±20.87
Antiangiogenic agents 18± 0
Etiology of MRONJ
Tooth extraction 29 (90.6)
Implant extraction 1 (3.1)
Spontaneously 2 (6.25)
Treatment modality
Surgical 18 (56.2)
Conservative 14(43.8)
(i) Data presented as n (%) or mean ± standard deviation.
BPs, bisphosphonate; IV, intravenous subcutaneous; MRONJ, medication-
related osteonecrosis of the jaw; PO, oral.
(ii) Treatment duration: exemption as values present number of months.
(iii) Sums to >100% because some patients used multiple medications.
(iv) IV: intravenous regime; IV+PO: intravenous + oral; some of the patients
received drugs by both ways.
patients with prostate carcinoma, four multiple myeloma
patients, and one patient with medullar thyroid carcinoma
(MTC) and renal cancer. Fourteen pts out of 21 pts with
malignant disease have got bone metastasis before onset of
MRONJ. Seventeen out of 21 pts with malignant disease
were on chemotherapy. The most commonly used drug was
Zoledronate (Table 1).
The stage system was according the AAOMS criteria [2].
After clinical diagnosis, patients undergo orthopantomogra-
phy and targeted CBCT. Radiographic findings showed either
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Figure 1: (a) Patient with medullary thyroid cancer, before and after conservative treatment. Patient just performed brushing exposed bone
with stick or spatula with chlorhexidine 0,12% solution. Significant improvement (b). Panoramic radiography (c) and cone beam computer
tomography rolled out bone sequestrum. (d) Scanora 3Dx device (On Demand Software Cybermed, Seoul, Korea.)
persisting and nonhealing tooth socket after extraction, often
accompanied with thickening of lamina dura, or radiolucent
osteolytic zones and superficial bone defects. To define pre-
operative stage and to achieve the most predictable treatment
outcome, targeted CBCT scan was performed (SCANORA
3Dx, Tuusula, Finland). The analysis of the bone structure
was performed by using ROI (region of interest) and profile
function to confirm/exclude bone sequestration. Dento-
maxillofacial radiologist evaluated all images (Figures 1–6).
Conservative treatment modality was utilized for stage
0-2 patients which included swab, systemic antibiotic treat-
ment, systemic administration of tocopherol and pentoxi-
fylline prescription, and brushing the lesion with spatula or
spatula (stick) for swab sampling in conjunctionwith solution
of chlorhexidine 0,12 % (oral antiseptic mouth rinses are
recommended). Surgical approach was performed for stages
2 and 3.
Patients without sequestration, either clinically or radio-
logically, were observed and just medications were prescribed
(Pentoxifylline tablets 400 mg per or twice daily). Antibiotic
treatment was given according to swab findings. Mouth
rinses (chlorhexidine solution 0,12%) were recommended in
periodical regime twice a day. For stage 3 disease patients,
sequestrectomy or radical bone removal was performed.
They were not suitable candidates for major reconstruc-
tive microsurgical reconstruction due to significant medical
comorbidities.
Figure 2: Stage III, MRONJ in the right mandibular corpus.
Radiolucency with sequestrum.
This study met the criteria for exemption by the institu-
tional review board.
3. Study Variables
3.1. Predictor Variables. The predictor group of variables
involved a varied group of variables divided into the following
groups: (1) demographic, (2) clinical data, and (3) treatment
modality.
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Figure 3: Stage III, MRONJ, with “iceberg” phenomena. (a) Small areawith pus in the frontal region of themandible. (b)OPGwith significant
bone destruction and sequestrum in frontal region. (c) Granulation, connective tissue with small abscess infiltrated with neutrophils, plasma
cells, and lymphocytes. The necrotic masses at surface. (d) Necrotic tissue with connective tissue, neutrophils, plasma cells, and granulocytes
(HE, x200)
(a) (b)
(c) (d)
Figure 4: Stage I MRONJ. (a) Intraoral detail. (b) Orthopantomograph and CBCT 3D mode and cross section analysis excluded any bony
sequestrum. (c) Axial view of CBCT confirmed our findings. (d) 3D mode view in Scanora 3D software is especially useful tool. Using 3D
zoom tool, it is very easy to eliminate other structures which could interfere with region of interest.
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Figure 5:MRONJ stage III. (a) Clinical appearance of bone sequestrum in themaxillary area. (b) Sequestrum removed. (c) Favourablewound
healing.
(a) (b)
(c)
Figure 6: (a) Radiological appearance of MRONJ. (b) Lesion cured. (c) Clinical appearance.
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The demographic variables involved sex and age at the
time of MRONJ diagnosis, the underlying disease (malig-
nant or nonmalignant), drugs used (BPS or antiangiogenic
agent), duration of exposure and way of administration,
chemotherapy, presence of bone metastasis, and trigger for
MRONJ developing (tooth extraction or trauma). Patients
were divided into the following groups regarding the way of
BPs administration: (1) only intravenously (IV), (2) IV+ oral
(PO), and (3) PO. All patients were clinically evaluated by a
maxillofacial surgeon.
Clinical data considered anatomic location of disease
(mandible, maxilla, or both) and disease stage at the first
presentation.
According to the treatment modalities patients are
divided into the following groups regarding the type of
treatment they had: conservative and surgical.
3.2. Outcome Variable. The clinical outcome was divided
in two groups: cured/improvement (resolution or positive
change of stadium 6 months after treatment) and stable/
progression (stability or negative change of stadium 6months
after treatment).
The patients were considered cured if complete healing of
mucosa over the exposed bone with pain relief had occurred.
The patients were considered improved if they were better
regarding the symptoms or had progressed to a lower disease
stage after the treatment [4–6]. If their disease had not
advanced to a higher stage, patients are considered stable.
Progression was considered if patients experienced more
severe pain, inflammation, or more bone exposure after the
treatment, with advances to a higher stage [4–6].
3.3. Statistical Analysis. AMicrosoft Excel database was used
for data collection and storing. The descriptive and analytic
statistics were computed. For each variable of interest, logistic
regression analysis was used to examine the association
between the outcome and the factor. All variables were
then involved in multivariable logistic regression analysis
to examine joint effects of those factors on the outcome.
Statistical significance was set at P <0.05 SPSS version 18.0
software was used for statistical calculations.
4. Results
Twenty-six patients totally were on IV regime (81.25%)
(Table 1). Only six pts (18.8 %) took bisphosphonates orally.
Five of them were on IV+PO regime (15.6%). Only one
patient received both zoledronic acid and sunitinib concomi-
tantly.
In twenty-three cases (72%) lesion occurred in the
mandible (6 in the anterior sextant and 18 in the posterior),
in 8 cases (25%) in the maxilla (1 in the anterior sextant and 7
in the posterior), and in 1 (3%) in both jaws (all occurring in
the posterior sextant). The average duration ofmedical agents
exposure varied between the different type of drugs. (Table 1).
Twenty-three patients (71.8%) developed lesions while
actively receiving bisphosphonate therapy.
The time range for the patients who developed disease
after terminating BPs treatment was between 4 and 84
months.
The main event leading to MRONJ development was
tooth extraction in 29 cases (91%), implant extraction in one
case (3.1%), and spontaneous type occurred in two cases (6%)
(Table 1).
21 bone biopsies were examined by pathologist. The find-
ings were consistent with a diagnosis of chronic osteomyelitis
that ruled out malignancy. Necrotic spaces showed empty
osteocyte lacunae with medullary spaces and surrounding
tissue colonized by Actinomyces like microorganisms. These
germs were confirmed in 10 cases (31%); however no statisti-
cal significance with clinical outcome and other parameters
were found (data not shown in table).
Eighteen patients (56.2 %) underwent surgery after ini-
tial antibiotic treatment, whereas fourteen patients (43.8%)
received only conservative treatment. Follow-up period range
was 6 to 63 months (mean 32.4 ± 16.8).
The variables which are compared to clinical outcome
are shown in Table 2. There was no statistical significance
in examined variables (sex, age, underlying disease, stage,
BPs intake groups, BPs treatment duration, aetiology, timing
of tooth extraction regarding the cessation of medications
related to MRONJ, and surgical approach between patients
who experienced clinical improvement or healing and those
who did not) (Table 2.)
Differences (but not statistically significant) are noted in
the gender, underlying disease, stage, BPs consumption, BPs
intake (way of administration), and surgical approach and
timing of extraction.
The percentage of response to therapy for male patients
was lower (54.5%) in comparison with female whereas treat-
ment response was better (71.4%). No statistical significance
was found in the treatment outcome between mandible and
maxilla. However premolar and frontal region of the upper
jaw responded excellently to the treatment (5 patients (100 %
cured or improved) in comparison with symphyseal part of
mandible (50%) and molar region of upper jaw (66%)).
No significant relationshipwas found between the stage of
the MRONJ and the modality or the duration of BP therapy.
However, patients who were on BPs therapy less than 12
months showed good response to treatment (5 patients, 80%
cured or improved) (Table 1.) However, patients who were
on BPs more than 12 months had more serious stage of
MRONJ. Patient who was on BPs and Sutent concomitantly
got the most severe stage of MRONJ of both jaws and was
nonresponsive to the therapy. He developed oronasal and
oroantral fistula.
The difference was observed between the group of pts
who received BPs PO and only IV, but without statistical
significance (Table 2).
Patients treated conservatively showed better response
to therapy (11 patients, 78.6%), but not without statistical
significance (Table 2).
The patients were staged as 0, I, II, and III, respectively, 0,
5, 18, and 9, regarding the staging system of AAOMS (Table 1)
[7].
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Table 2: Crosstab between study variables and clinical outcome.
Study Variables Clinical outcome total
cured/improvement, N (%) stable/progression N (%)
Sex
Male 6 (54.5%) 5 (45.5%) 11
Female 15 (71.4%) 6 (28.6%) 21
Total 21 (65.6%) 11 (34.4%) 32
Age
<50 years 3 (60%) 2 (40%) 5
> 50 years 18 (66.7%) 9 (33.3%) 27
Underlying disease
Osteoporosis 8 (72.7%) 3 (27.3%) 11
Malignant 13 (61.9%) 8 (38.1%) 21
Stage
I 4 (80%) 1 (20%) 5
II 12 (66.7%) 6 (33.3) 18
III 5 (55.6%) 4 (44.4%) 9
BPs consumption
<12 months 4 (80%) 1 (20%) 5
12 to 36 11 (61.1%) 7 (38.9%) 18
>36 months 6 (66.7%) 3 (33.3%) 9
BPs intake
IV+(IV+PO) 16 (61.5%) 10 (38.7%) 26
PO 5 (83.3%) 1 (16.7%) 6
(IV+PO) +PO 9 (81.8%) 2 (18.2) 11
IV 12 (57.1%) 9 (42.9%) 21
TIMING OF TOOTH EXTRACTION
During BPs therapy 16 (69.6%) 7 (30.4%) 23
After cessation of BPs therapy 5 (55.6%) 4 (44.4%) 9
Chemotherapy
Yes 11 (64.7%) 6 (35.3%) 7
No 2(50%) 2(50%) 4
Bone metastasis
Yes 9 (64.3%) 5 (35.7%) 14
No 4 (57.1%) 3 (42.9%) 7
Localisation
mandible 15 (65.2%) 8 (34.8%) 23
maxilla 6 (66.7%) 3 (33.3%) 9
Etiology
dental extraction-trauma 20 (66.6%) 10 (33.4%) 30
No dental extraction 1 (50 %)) 1 (50%) 2
Surgical approach
Surgical 10 (55.6%) 8 (44.4%) 18
Conservative 11 (78.6%) 3 (21.4%) 14
(i) Data presented as n (%) or mean ± standard deviation.
Disease outcome was considered clinically as cured/im-
provement and stable/progression 66%and 34%, respectively.
5. Discussion
MRONJ is a disease with very unpredictable outcome. There
is a serious adverse effect of bisphosphonate therapy due to
its incompletely clarified etiopathogenesis [2]. None of the
proposed theories concerning etiopathogenesis of MRONJ
has found scientific approval and confirmation [8]. These
theories mostly explain MRONJ because of inhibition [5] of
bone remodelling process, antiangiogenic potential of bis-
phosphonates, direct toxic effect on oral epithelium, or their
associated negative effects with infection and inflammation.
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To consider MRONJ disease 2 parameters need to be
evaluated: therapeutic indications and types of medication
(Tables 1 and 2). Patients at risk of MRONJ are often
subdivided into two subcategories: low risk (osteoporosis;
oral medication) and high risk (cancer patients, etc.).
MRONJ was confirmed mostly in females (65.6%) which
is previously reported [9]. One of the reasons which could
explain the frequency of disease in females could be the
higher incidence of breast cancer in females and skeletal
metastasis. This disease presents one of the main indications
for BPs therapy. The age and gender as risk factors are
inconsistently presented in the scientific literature [10, 11].
Previous studies have reported that risk of developing
MRONJ is higher in cases with intravenous administration
of bisphosphonates, especially when more potent amino
bisphosphonates are used, and increaseswith bisphosphonate
therapy duration and dosage [2, 3].
Themajority of patients in this study were on intravenous
drug regime (81.2%). Patients from the study who were on
BPs more than 12 months had more serious stage of MRONJ
with lower percentage of favourable outcome. The risk is
also higher in patients with underlying malignant disease
[2, 12, 13], which was recorded for the majority of our patients
(67%).
Most of the patients were on drugs related to MRONJ at
the time of tooth extraction. The reason should be the lack
of preventive measures and inadequate healthcare awareness
of physicians regarding the side effect of MRONJ related
drugs. Tooth extraction was the most frequent local risk, i.e.,
triggering factor for developing MRONJ along with other
invasive dental interventions, which was also the case in
this study group of patients (91%). Inadequate dentures that
compress oral mucosa against bony prominences might also
be the initiating factor for MRONJ development [14]. We got
two patients with spontaneous MRONJ and one of them was
cured. There is a lack of published cases with regard to the
outcome of spontaneously developed MRONJ [15, 16]. There
is no statistically significant association between the outcome
and subsite of MRONJ in the jaws or primary disease on the
other side. However, in our study premolar and frontal region
of the upper jaw responded excellently to the treatment (100%
cured or improved).
Besides patients with diagnosis of osteoporosis, all others
from our study group had underlying malignant disease
and were receiving high potent-nitrogen containing BPs or
antiangiogenic medication in addition to chemotherapy, all
of which, according to references data, increase risk of devel-
oping MRONJ. Some of the patients received corticosteroids,
which also increased the risk of developingMRONJ and even
more complicated its improvement [5, 10, 11].
Clinical findings in patients of current study aremostly in
agreement with clinical findings in other reported researches,
according to the illness staging. Although there were four
patients in stage III with extensive osteolytic process, only
one of them developed oroantral communication. That was
the patient with advanced renal cancer who was on BPs
and antiangiogenic drugs simultaneously. This simultaneous
therapy is associated with less favourable outcome [10, 17].
The patients who present such a serious stage ofMRONJ after
concomitant BPs and chemotherapy could be eligible candi-
dates for radical resection of the lesion and reconstruction
with microvascular free flaps [18]. It should be highlighted
that patients with MRONJ require meticulous preoperative
assessment to avoid failure in treatment. MRONJ is located
predominantly in mandible, which is logical, because maxilla
is relatively spared due to better vascularisation and because
of the difference in the anatomy [4, 19].
The panoramic radiograph is widely used imaging
method in MRONJ patients, but panoramic image findings
are not specific and could vary from predominantly sclerotic
to predominantly lytic bone changes or their mixture [20, 21].
MDCT or MRI are considered the techniques with higher
detectability and more sensitive methods for evaluation of
bone necrotic process extension [22].
Preoperative assessment with cone beam computer
tomography (CBCT) could be very powerful diagnostic tool
in differential diagnosis, staging, prediction, and treatment
planning [23].
However, in some cases due to similarity in the radio-
graphic pattern, in some cases, it could be difficult to differen-
tiateMRONJ frommalignant process invasion, osteomyelitis,
or consequences of radiotherapy to the orofacial region.
Therefore, the history of radiation therapy and malignant
process must be excluded before diagnosis of MRONJ is
made. CBCT in this study was performed inmajority of cases
and showed high specificity to exclude bone sequestrum.
Generally, there are no sensitive characteristic histopath-
ological features which would help MRONJ recognition [7].
Histological examination in all patients revealed osteonecro-
sis without pathological signs of malignancy. MRONJ was
presented by avascular type of osteonecrosis. It was charac-
terised with osteocyte-depleted bone lacunae. This specific
type of avascular necrosis might have wide range of diversity
[7]. However, the histology presents just piece of the complex
puzzle in establishing diagnosis of MRONJ. Certainly, in
this diagnostic step, it is very important to exclude primary
malignant process or metastasis. On the other hand, some-
times it is difficult to assess whether biopsy should be taken,
because unnecessary intervention may interrupt healing
and exacerbate osteonecrosis. We believe that, after detailed
anamnesis and clinical and radiographic examination, biopsy
should be taken into consideration occasionally, in order to
exclude potential malignant process which requires different
kind of treatment, except in stages 0 and I.
Treatment protocol for MRONJ according to AOOMS
recommendations is satisfactory, well accepted, and admin-
istered in our departments as well. Nevertheless, MRONJ
is a condition without predictable and confident treatment
outcome. It is well known that, in many cases, despite
applied therapeutic measures, exposed necrotic bone cannot
heal, especially when bisphosphonate therapy is not termi-
nated. Discontinuation of bisphosphonate therapy cannot
always be done, especially in oncologic patients, because
that might interrupt malignant disease treatment. That cer-
tainly demands cooperation of oral or maxillofacial surgeon
and oncologist. Otto and others have proposed the newest
algorithm recently [12]. Clinical outcome in the literature
varies. Some studies show high rate of success in treatment
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[24, 25]. According to one of the last reviews, good results
were achieved in early stages, but heterogenous results in the
advanced stages (50-100%) [26, 27].
Patients on bisphosphonate, antiresorptive, or antiangio-
genic therapy must be educated how to recognise MRONJ
or its symptoms, in order to contact their physician in
time, so that they could be promptly referred to the oral or
maxillofacial surgeon.
6. Conclusion
This paper presents and describes the ubiquitous inexplicable
adverse effect of bisphosphonate therapy in patients included
in this study. Total success rate of the management was
satisfactory. Although no statistical significance was reached
between patient related factors and final treatment outcome,
the highest success rate is achieved if treatment starts in stage
1.
Medical doctors should be aware of this medical related
disease and the role of dental evaluation before induction of
these drugs as the cure rate is still not predictable. It must be
highlighted that the collaboration between a physician and a
dentist as well as a maxillofacial surgeon should be initiated
before induction of these drugs. The future case control or
randomized studies should be performed as there is the lack
of these studies so far.
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